MAPT and Alzheimer disease: The disease-modifying potential of AChEIs for AD therapy has encouraged the development of new AChE-based multitarget/network medicines, especially new medicines that can positively modulate the process of Aβ production and tau phosphorylation, but do not initiate AChE expression [84,85].